Pharmacological properties of combination therapies for hypertension

Darrell R. Abernethy

Research output: Contribution to journalArticle

Abstract

Single drug therapy for the treatment of hypertension has traditionally been a standard of practice. More recently combination therapy as first-line treatment has gained acceptance both by the medical practice community and the US Food and Drug Administration. The advantages of combinations may be a synergistic or additive antihypertensive effect, metabolic improvement, or both. The combination of a thiazide-type diuretic and a potassium-sparing diuretic has been quite useful in the past to prevent the need for potassium supplementation. The combination of β-adrenoceptor blockade and a thiazide diuretic results in an additive antihypertensive effect that permits the effective use of very low thiazide doses. The mechanism of antihypertensive effects of each member of the combination are complimentary with increased sympathetic outflow and renin-angiotensin axis activation induced by the diuretic being blunted by β1-adrenergic blockade. Combinations not used as first-line therapy, such as angiotensin converting enzyme inhibitors or angiotensin receptor blockade and a thiazide diuretic, have complimentary antihypertensive mechanisms and have been useful in treating patient groups who do not respond well to converting enzyme inhibitor monotherapy. The combination of a calcium antagonist with diuretic therapy has an additive hypertensive effect as well; however, the complimentary mechanisms are less obvious. Finally, the combination of angiotensin converting enzyme inhibition and calcium antagonist therapy has been useful in selected patients, but again the complimentary mechanisms are less obvious. As first-line therapy, combinations for diuretics and β1-receptor blockers have been useful for achieving increased antihypertensive effect with decreased adverse drug effect.

Original languageEnglish (US)
JournalAmerican Journal of Hypertension
Volume10
Issue number3
DOIs
StatePublished - Mar 1997
Externally publishedYes

Fingerprint

Pharmacology
Hypertension
Antihypertensive Agents
Sodium Chloride Symporter Inhibitors
Diuretics
Therapeutics
Potassium Sparing Diuretics
Calcium
Thiazides
Angiotensin Receptors
Angiotensins
Enzyme Inhibitors
Peptidyl-Dipeptidase A
United States Food and Drug Administration
Angiotensin-Converting Enzyme Inhibitors
Renin
Adrenergic Agents
Adrenergic Receptors
Potassium
Drug Therapy

Keywords

  • β-adrenoceptor blocker
  • angiotensin converting enzyme inhibitor
  • angiotensin receptor blocker
  • antihypertensive therapy
  • calcium antagonist
  • combination therapy
  • diuretic
  • drug

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Pharmacological properties of combination therapies for hypertension. / Abernethy, Darrell R.

In: American Journal of Hypertension, Vol. 10, No. 3, 03.1997.

Research output: Contribution to journalArticle

@article{edd66c9142924e3ca839b67f2219b9a2,
title = "Pharmacological properties of combination therapies for hypertension",
abstract = "Single drug therapy for the treatment of hypertension has traditionally been a standard of practice. More recently combination therapy as first-line treatment has gained acceptance both by the medical practice community and the US Food and Drug Administration. The advantages of combinations may be a synergistic or additive antihypertensive effect, metabolic improvement, or both. The combination of a thiazide-type diuretic and a potassium-sparing diuretic has been quite useful in the past to prevent the need for potassium supplementation. The combination of β-adrenoceptor blockade and a thiazide diuretic results in an additive antihypertensive effect that permits the effective use of very low thiazide doses. The mechanism of antihypertensive effects of each member of the combination are complimentary with increased sympathetic outflow and renin-angiotensin axis activation induced by the diuretic being blunted by β1-adrenergic blockade. Combinations not used as first-line therapy, such as angiotensin converting enzyme inhibitors or angiotensin receptor blockade and a thiazide diuretic, have complimentary antihypertensive mechanisms and have been useful in treating patient groups who do not respond well to converting enzyme inhibitor monotherapy. The combination of a calcium antagonist with diuretic therapy has an additive hypertensive effect as well; however, the complimentary mechanisms are less obvious. Finally, the combination of angiotensin converting enzyme inhibition and calcium antagonist therapy has been useful in selected patients, but again the complimentary mechanisms are less obvious. As first-line therapy, combinations for diuretics and β1-receptor blockers have been useful for achieving increased antihypertensive effect with decreased adverse drug effect.",
keywords = "β-adrenoceptor blocker, angiotensin converting enzyme inhibitor, angiotensin receptor blocker, antihypertensive therapy, calcium antagonist, combination therapy, diuretic, drug",
author = "Abernethy, {Darrell R.}",
year = "1997",
month = "3",
doi = "10.1016/S0895-7061(97)00018-6",
language = "English (US)",
volume = "10",
journal = "Journal of clinical hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Pharmacological properties of combination therapies for hypertension

AU - Abernethy, Darrell R.

PY - 1997/3

Y1 - 1997/3

N2 - Single drug therapy for the treatment of hypertension has traditionally been a standard of practice. More recently combination therapy as first-line treatment has gained acceptance both by the medical practice community and the US Food and Drug Administration. The advantages of combinations may be a synergistic or additive antihypertensive effect, metabolic improvement, or both. The combination of a thiazide-type diuretic and a potassium-sparing diuretic has been quite useful in the past to prevent the need for potassium supplementation. The combination of β-adrenoceptor blockade and a thiazide diuretic results in an additive antihypertensive effect that permits the effective use of very low thiazide doses. The mechanism of antihypertensive effects of each member of the combination are complimentary with increased sympathetic outflow and renin-angiotensin axis activation induced by the diuretic being blunted by β1-adrenergic blockade. Combinations not used as first-line therapy, such as angiotensin converting enzyme inhibitors or angiotensin receptor blockade and a thiazide diuretic, have complimentary antihypertensive mechanisms and have been useful in treating patient groups who do not respond well to converting enzyme inhibitor monotherapy. The combination of a calcium antagonist with diuretic therapy has an additive hypertensive effect as well; however, the complimentary mechanisms are less obvious. Finally, the combination of angiotensin converting enzyme inhibition and calcium antagonist therapy has been useful in selected patients, but again the complimentary mechanisms are less obvious. As first-line therapy, combinations for diuretics and β1-receptor blockers have been useful for achieving increased antihypertensive effect with decreased adverse drug effect.

AB - Single drug therapy for the treatment of hypertension has traditionally been a standard of practice. More recently combination therapy as first-line treatment has gained acceptance both by the medical practice community and the US Food and Drug Administration. The advantages of combinations may be a synergistic or additive antihypertensive effect, metabolic improvement, or both. The combination of a thiazide-type diuretic and a potassium-sparing diuretic has been quite useful in the past to prevent the need for potassium supplementation. The combination of β-adrenoceptor blockade and a thiazide diuretic results in an additive antihypertensive effect that permits the effective use of very low thiazide doses. The mechanism of antihypertensive effects of each member of the combination are complimentary with increased sympathetic outflow and renin-angiotensin axis activation induced by the diuretic being blunted by β1-adrenergic blockade. Combinations not used as first-line therapy, such as angiotensin converting enzyme inhibitors or angiotensin receptor blockade and a thiazide diuretic, have complimentary antihypertensive mechanisms and have been useful in treating patient groups who do not respond well to converting enzyme inhibitor monotherapy. The combination of a calcium antagonist with diuretic therapy has an additive hypertensive effect as well; however, the complimentary mechanisms are less obvious. Finally, the combination of angiotensin converting enzyme inhibition and calcium antagonist therapy has been useful in selected patients, but again the complimentary mechanisms are less obvious. As first-line therapy, combinations for diuretics and β1-receptor blockers have been useful for achieving increased antihypertensive effect with decreased adverse drug effect.

KW - β-adrenoceptor blocker

KW - angiotensin converting enzyme inhibitor

KW - angiotensin receptor blocker

KW - antihypertensive therapy

KW - calcium antagonist

KW - combination therapy

KW - diuretic

KW - drug

UR - http://www.scopus.com/inward/record.url?scp=0030929736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030929736&partnerID=8YFLogxK

U2 - 10.1016/S0895-7061(97)00018-6

DO - 10.1016/S0895-7061(97)00018-6

M3 - Article

VL - 10

JO - Journal of clinical hypertension

JF - Journal of clinical hypertension

SN - 0895-7061

IS - 3

ER -